

# HOME-CoV - Hospitalization or Outpatient Management of patients with a proven or probable SARS-CoV-2 infection

Head :DOUILLET Delphine

Last update : 02/05/2021 | Version : 1 | ID : 73649

General	
Identification	
Detailed name	Hospitalization or Outpatient Management of patients with a proven or probable SARS-CoV-2 infection
Sign or acronym	HOME-CoV
General Aspects	
Medical area	Emergency medicine
Study in connection with Covid-19	Yes
Health determinants	Healthcare system and access to health care services
Keywords	COVID-19; Hospitalization; Outpatient; Rule validation; Expert consensus; Rule-based decision-making; Clinical support decision tool.
Scientific investigator(s) (Contact)	
Name of the director	DOUILLET
Surname	Delphine
Email	Delphine.Douillet@chu-angers.fr
Collaborations	
Funding	
Funding status	Public
Details	CHU Angers
Governance of the database	
Sponsor(s) or organisation(s) responsible	CHU Angers

Organisation status	
Additional contact	
Email	loic.carballido@chu-angers.fr
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	Yes
Details	Performed at group level (clusters)
Database objective	
Main objective	<p>the composite rate of adverse outcomes [ Time Frame: day 7 ]</p> <p>Adverse outcomes include intubation with mechanical ventilation requirement and death (Stage ? 6 on "Ordinal Scale for Clinical Improvement" of the World Health Organization) within 7 days after inclusion.</p>
Inclusion criteria	<p>The rate of hospitalization [ Time Frame: 24 hours ]</p> <p>The rate of patients hospitalized after admission to the emergency room including patients discharged home more than 24 hours after admission.</p> <p>It will be analyzed in a hierarchical approach, only if first primary objective is positive i.e. non-inferiority of HOME-CoV strategy versus current practice on the rate of adverse outcomes.</p>
Population type	
Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p>

Great age (80 years and more)

Population covered

Sick population

Pathology

J12 - Viral pneumonia, not elsewhere classified

Gender

Male  
Woman

Geography area

International

Detail of the geography area

France Belgium

## Data collection

Dates

Size of the database

Size of the database (number of individuals)

[1000-10 000[ individuals

Details of the number of individuals

4000

## Data

Database activity

Current data collection

Type of data collected

Clinical data  
Declarative data  
Paraclinical data  
Biological data  
Administrative data

Clinical data (detail)

Direct physical measures  
Medical registration

Declarative data (detail)

Face to face interview  
Phone interview

## Procedures

Participant monitoring

Yes

Monitoring procedures

Monitoring by contact with the participant (mail, e-mail, telephone etc.)

## Promotion and access

Promotion

